Abstract:Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB) antibodies, have demonstrated the capacity of the immune system to fight cancer in a number of malignancies such as melanoma and lung cancer. The numbers, localization and phenotypes of tumor-infiltrating lymphocytes (TIL) are not only predictive of response to immunotherapy but also key modulators of disease progression. In this review, we focus on TIL profiling in cutaneous melanoma using histopathological approaches and highlight the observed prognostic value of the primary TIL subsets. The quantification of TIL in formalin-fixed tumor samples ranges from visual scoring of lymphocytic infiltrates in H&E to multiplex immunohistochemistry and immunofluorescence followed by enumeration using image analysis software. Nevertheless, TIL enumeration in the current literature primarily relies upon single marker immunohistochemistry analyses of major lymphocyte subsets such as conventional T cells (CD3, CD4, CD8), regulatory T cells (FOXP3) and B cells (CD20). We review key studies in the literature on associations between TIL subsets and patient survival. We also cover recent findings with respect to the existence of ectopic lymphoid aggregates found in the TME which are termed tertiary lymphoid structures (TLS) and are generally a positive prognostic feature. In addition to their prognostic significance, the existence of various TIL sub-populations has also been reported to predict a patient's response to ICB. Thus, the literature on the predictive potential of TIL subsets in melanoma patients receiving ICB has also been discussed. Finally, we describe recently developed state-of-the-art profiling approaches for tumor infiltrating immune cells such as digital pathology scoring algorithms (e.g., Immunoscore) and multiplex proteomics-based immunophenotyping platforms (e.g., imaging mass cytometry). Translating these novel technologies have the potential to revolutionize tumor immunopathology leading to altering our current understanding of cancer immunology and dramatically improving outcomes for patients.

Tumor-infiltrating lymphocytes for melanoma immunotherapy

Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment

Into the Future: Fighting Melanoma with Immunity

Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1

Tumor-infiltrating γδ T cells as targets of immune checkpoint blockade in melanoma

Immunomodulatory therapy for melanoma: ipilimumab and beyond

Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions

Advances in treatment of melanoma with immunotherapy

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Therapeutic options in cutaneous melanoma: latest developments

[Targeted therapies for melanoma]

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma